The promising results obtained with anti-GD2 therapy in combination with IL-2 and GM-CSF in NB patients with metastatic disease at diagnosis raises the question of how ADCC is affected by the NB immunosuppressive microenvironment. Here, IL2 is linked to neuroblastoma.